Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years tags : Cancer save search
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Published: 2024-04-25 (Just crawled : 13:00) - globenewswire.com
MYNZ | $0.8987 3.42% 3.34% 5.6K
|
| Email alert
Add to watchlist
fda integration diagnostic mrna positive cancer for topline trial biomarkers results study
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Published: 2024-04-25 (Crawled : 12:00) - biospace.com/
CGEN | $1.91 -3.54% 3.45% 1.2K
|
Health Technology
| Email alert
Add to watchlist
com701 liver asco cancer
Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
Published: 2024-04-25 (Crawled : 12:00) - biospace.com/
ARAY | $2.205 0.23% 29K
|
Health Technology
| Email alert
Add to watchlist
cancer treatment solutions therapy
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Published: 2024-04-25 (Crawled : 11:00) - globenewswire.com
PPBT | $0.5127 4.63% 9.09% 980K
|
Manufacturing
| Email alert
Add to watchlist
cm24 presentation asco cancer pancreatic meeting purple study
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Published: 2024-04-25 (Crawled : 08:00) - biospace.com/
IBRX | $4.82 -12.2% -14.02% 700K
|
Manufacturing
|
| O: -6.99%
H: 0.0%
C: 0.0%
fda anktiva lung positive cancer cell for meeting results
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FGEN | $0.9165 -6.89% 160K
|
Health Technology
| Email alert
Add to watchlist
fg-3246 cancer meeting study
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.34 2.36% 2.39% 740
|
Health Technology
|
| O: 0.33%
H: 2.48%
C: 2.07%
lung asco cancer cell for trial results
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
BNGO | $0.761 -0.01% 99K
|
Health Technology
|
| O: -0.62%
H: 2.53%
C: -3.8%
cancer publication
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.47 400K
|
Manufacturing
|
| O: -1.05%
H: 0.85%
C: 0.85%
TAK | News | $13.23 -1.12% 0.23% 690
|
Health Technology
|
| O: -0.19%
H: 0.08%
C: -0.68%
granted approval cancer treatment for
FDA Rejects Abeona’s Gene Therapy, Approves ImmunityBio’s Bladder Cancer Treatment
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PRGO | $31.23 2.43% 0.0% 210
|
Health Technology
|
| O: 0.13%
H: 1.89%
C: 1.3%
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
ABT | News | $106.76 -0.12% 150K
|
Health Technology
|
| O: 0.56%
H: 0.41%
C: -0.07%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
fda bladder cancer treatment
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
ARTL | News | $1.3418 1.3K
|
Health Technology
|
| O: 0.77%
H: 2.29%
C: 0.0%
cancer publication therapy
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 1K
|
Health Technology
|
| O: 12.36%
H: 8.33%
C: 6.67%
atile-002 versamune biotech hpv cancer key trial
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $148.04 2.72% 24K
|
Health Technology
|
| O: 3.5%
H: 4.77%
C: 2.39%
lung approval cancer cell treatment for
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $4.82 -12.2% -14.02% 700K
|
Manufacturing
|
| O: 16.59%
H: 0.65%
C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Published: 2024-04-22 (Crawled : 20:00) - globenewswire.com
TOVX | News | $0.3686 3.5K
|
Manufacturing
|
| O: 2.44%
H: 0.0%
C: -9.52%
vcn-01 cancer pancreatic cell preclinical for meeting potential therapy
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
NVO | News | $126.16 -1.93% -2.81% 100K
|
Health Technology
|
| O: -0.1%
H: 2.99%
C: 2.18%
snipr001 cancer trials funding
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 35
|
Health Technology
|
| O: 6.74%
H: 5.26%
C: 0.35%
lung pharma japan approval cancer cell for trial
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Published: 2024-04-22 (Crawled : 17:00) - biospace.com/
VCYT | News | $19.34 -2.81% 8.5K
|
Health Technology
|
| O: 1.03%
H: 2.65%
C: 1.02%
active test cancer for study
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
GH | News 4 | $17.38 -3.98% 72K
|
Health Services
|
| O: 4.42%
H: 5.36%
C: 4.83%
fda test review cancer blood for
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1699 1.13% 1.41% 1.5M
|
Health Technology
|
| O: 6.25%
H: 17.65%
C: 5.88%
health congress cancer care family
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.